BofA Securities Maintains Boston Scientific(BSX.US) With Buy Rating

美银证券维持波士顿科学(BSX.US)买入评级

moomoo资讯 · 2024/10/28 07:31 · 评级/大行评级

BofA Securities analyst Travis Steed maintains $Boston Scientific (BSX.US)$ with a buy rating.

According to TipRanks data, the analyst has a success rate of 64.1% and a total average return of 8.2% over the past year.

AnalystRecentRatingAutoNews_205143_20241028_ced443c6ebceea44693e9bacdbd74bf1ec5f6708_1730161824248447_mm_en

Furthermore, according to the comprehensive report, the opinions of $Boston Scientific (BSX.US)$'s main analysts recently are as follows:

Boston Scientific has delivered a quarter that exceeded expectations from all angles, despite the high anticipations. Nonetheless, the shares are currently under pressure due to the announced suspension of the AVANT GUARD clinical trial, which is investigating Farapulse in a new patient segment. It's essential to note that this patient segment is not currently being treated, there are certain observations under assessment, and the expectation is for enrollment to continue shortly.
Boston Scientific's Q3 outcomes were described as 'impressive', and the company's management has elevated its 2024 guidance, with expectations to conclude the year with +15% organic sales growth. Despite a temporary halt in the EP trial AVANTGUARD, which influenced the stock negatively, the reaction is perceived to be exaggerated according to key opinion leader assessments.
The AVANT Guard trial setback is not associated with a mortality event or initiated by the FDA, and the momentum of global Farapulse is viewed as sustainable over the medium term. It is believed that the current pullback in Boston Scientific shares offers a compelling entry point.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

美银证券分析师Travis Steed维持$波士顿科学 (BSX.US)$买入评级。

根据TipRanks数据显示，该分析师近一年总胜率为64.1%，总平均回报率为8.2%。

AnalystRecentRatingAutoNews_205143_20241028_ced443c6ebceea44693e9bacdbd74bf1ec5f6708_1730161824248447_mm_sc

此外，综合报道，$波士顿科学 (BSX.US)$近期主要分析师观点如下：

尽管期望很高，但从各个角度来看，波士顿科学的季度业绩都超出了预期。尽管如此，由于宣布暂停Avant GUARD临床试验，该股目前仍处于压力之下，该股正在调查新患者领域的Farapulse。值得注意的是，该患者群目前尚未接受治疗，有某些观察结果正在评估中，预计很快就会继续入组。
波士顿科学第三季度的业绩被描述为 “令人印象深刻”，该公司的管理层提高了2024年的预期，预计今年年底有机销售增长将达到+15％。尽管EP试验AVANTGUARD暂时停止，对该股产生了负面影响，但根据主要意见领袖的评估，这种反应被认为被夸大了。
Avant Guard试验的挫折与死亡事件无关，也与美国食品药品管理局发起的死亡事件无关，全球Farapulse的势头被认为在中期内是可持续的。据信，波士顿科学公司股票当前的回调提供了一个引人注目的切入点。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

BofA Securities Maintains Boston Scientific(BSX.US) With Buy Rating

BofA Securities Maintains Boston Scientific(BSX.US) With Buy Rating

风险及免责提示

声明